Using a blood clotting factor to treat acute brain bleeding quickly
FVIIa for Acute hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial
This study is looking at whether giving a special medication called rFVIIa to people who have a sudden brain bleed can help them recover better when it's given quickly, along with regular treatment, and it involves 860 patients from different countries.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11014938 on NIH RePORTER |
What this research studies
This research investigates the use of recombinant Factor VIIa (rFVIIa) in patients experiencing acute intracerebral hemorrhage (ICH). The trial aims to determine if administering rFVIIa within two hours of symptom onset, alongside standard treatment, can improve patient outcomes compared to standard treatment alone. The study will involve 860 patients across multiple countries and will utilize mobile stroke units to expedite treatment. Participants will be monitored for their recovery over 90 days using a standardized scale.
Who could benefit from this research
Good fit: Ideal candidates are individuals aged 80 or younger who have experienced a spontaneous intracerebral hemorrhage and can be treated within two hours of symptom onset.
Not a fit: Patients with larger volumes of hemorrhage or those with significant intraventricular hemorrhage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve recovery outcomes for patients suffering from acute brain hemorrhages.
How similar studies have performed: Previous studies have shown promising results with similar approaches in treating acute strokes, indicating potential for success in this trial.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Broderick, Joseph Paul — University of Cincinnati
- Study coordinator: Broderick, Joseph Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.